[go: up one dir, main page]

AR017079A1 - A PHARMACEUTICAL COMPOSITION, A PROCEDURE FOR THE PREPARATION OF THE SAME, A TREATMENT METHOD AND ITS USE. - Google Patents

A PHARMACEUTICAL COMPOSITION, A PROCEDURE FOR THE PREPARATION OF THE SAME, A TREATMENT METHOD AND ITS USE.

Info

Publication number
AR017079A1
AR017079A1 ARP980104487A ARP980104487A AR017079A1 AR 017079 A1 AR017079 A1 AR 017079A1 AR P980104487 A ARP980104487 A AR P980104487A AR P980104487 A ARP980104487 A AR P980104487A AR 017079 A1 AR017079 A1 AR 017079A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
preparation
procedure
same
treatment method
Prior art date
Application number
ARP980104487A
Other languages
Spanish (es)
Original Assignee
West Christopher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Christopher filed Critical West Christopher
Publication of AR017079A1 publication Critical patent/AR017079A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composicion farmacéutica, un proceso para la preparacion de la misma, un método de tratamiento y su uso, donde dicha composicion farmacéutica comprendemicropartículas poliméricas que incluyen una droga, preferentemente olanzapina, y un ácido graso, cuya composicion puede ser adaptada para proveer unavelocidad de liberacion de droga que es aproximadamente lineal en el tiempo, y que tiene un efecto de liberacion repentina o explosiva insignificante.Pharmaceutical composition, a process for the preparation thereof, a method of treatment and its use, wherein said pharmaceutical composition comprises polymeric particles comprising a drug, preferably olanzapine, and a fatty acid, whose composition can be adapted to provide a speed of release of drug that is approximately linear in time, and that has an insignificant sudden or explosive release effect.

ARP980104487A 1997-09-09 1998-09-09 A PHARMACEUTICAL COMPOSITION, A PROCEDURE FOR THE PREPARATION OF THE SAME, A TREATMENT METHOD AND ITS USE. AR017079A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9718986.4A GB9718986D0 (en) 1997-09-09 1997-09-09 Controlled release microsphere delivery system

Publications (1)

Publication Number Publication Date
AR017079A1 true AR017079A1 (en) 2001-08-22

Family

ID=10818687

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104487A AR017079A1 (en) 1997-09-09 1998-09-09 A PHARMACEUTICAL COMPOSITION, A PROCEDURE FOR THE PREPARATION OF THE SAME, A TREATMENT METHOD AND ITS USE.

Country Status (10)

Country Link
EP (1) EP1011680A2 (en)
JP (1) JP2001515862A (en)
AR (1) AR017079A1 (en)
AU (1) AU745511B2 (en)
CA (1) CA2302762A1 (en)
GB (1) GB9718986D0 (en)
NO (1) NO20001219L (en)
NZ (1) NZ502710A (en)
WO (1) WO1999012549A2 (en)
ZA (1) ZA987762B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
ES2169980B1 (en) * 1999-12-17 2003-11-01 Lipotec Sa MICROCAPSULES FOR THE PROLONGED RELEASE OF PHARMACOS.
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US20020114843A1 (en) 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
CA2490351C (en) 2002-06-25 2011-11-01 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
BR0315895A (en) * 2002-10-31 2005-10-04 Pfizer Prod Inc Solid and semi-solid polymeric ionic conjugates, pharmaceutical composition, process for preparing said conjugates and solid or semi-solid composition
PT1675573E (en) 2003-10-23 2008-12-30 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
KR101040415B1 (en) 2004-04-15 2011-06-09 알케르메스,인코포레이티드 Polymer Base Sustained Release Method
RU2007106036A (en) 2004-08-31 2008-10-10 Пфайзер Продактс Инк. (Us) ANTIBODY TO CD40: DRUG AND METHODS
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20100098735A1 (en) * 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
AR064381A1 (en) 2006-12-18 2009-04-01 Takeda Pharmaceutical COMPOSITION OF SUSTAINED RELEASE AND METHODS TO PRODUCE
CN101715340A (en) 2007-04-23 2010-05-26 精达制药公司 Suspension formulation of insulinotropic peptide and application thereof
JP4879349B2 (en) 2007-07-31 2012-02-22 大塚製薬株式会社 Method for producing aripiprazole suspension and lyophilized preparation
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
KR102093612B1 (en) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 Rapid establishment and/or termination of substantial steady-state drug delivery
PL2642993T3 (en) * 2010-11-25 2016-09-30 Compositions of rotigotine or pharmaceutically acceptable salts of rotigotine
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JO3410B1 (en) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd Aripiprazole Lyophilized Formula
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
RU2760007C2 (en) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Polypeptides selective to glucagon receptors and their application methods
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
JP2020511483A (en) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ Sustained-release olanzapine preparation
KR102045721B1 (en) * 2019-03-27 2019-11-18 주식회사 씨트리 Compositions of dispersion phase for preparation of apixaban loaded microsphere and biocompatible polymer based apixaban loaded microsphere prepared therefrom

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
CA2148823C (en) * 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
IL117612A0 (en) * 1995-03-24 1996-07-23 Lilly Co Eli Granule formulation for olanzapine

Also Published As

Publication number Publication date
WO1999012549A2 (en) 1999-03-18
CA2302762A1 (en) 1999-03-18
ZA987762B (en) 2000-02-28
EP1011680A2 (en) 2000-06-28
JP2001515862A (en) 2001-09-25
NO20001219D0 (en) 2000-03-09
GB9718986D0 (en) 1997-11-12
WO1999012549A3 (en) 1999-05-06
AU8992598A (en) 1999-03-29
AU745511B2 (en) 2002-03-21
NZ502710A (en) 2001-09-28
NO20001219L (en) 2000-03-09

Similar Documents

Publication Publication Date Title
AR017079A1 (en) A PHARMACEUTICAL COMPOSITION, A PROCEDURE FOR THE PREPARATION OF THE SAME, A TREATMENT METHOD AND ITS USE.
MX9203116A (en) COMPOSITE ARTICLE INCLUDING ORIENTED MICROSTRUCTURES AND METHOD FOR ITS MANUFACTURE.
ES2148198T3 (en) PROCEDURE FOR CRUSHING PHARMACEUTICAL SUBSTANCES.
ES2177022T3 (en) AN ITRACONAZOL THAT EXHIBITS AN IMPROVED SOLUBILITY, A METHOD FOR PREPARING THE SAME AND A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT UNDERSTANDS THE SAME.
MX9201782A (en) PARTICLES OF BIOLOGICALLY ACTIVE SUBSTANCES, SUBSTANTIALLY INSOLUBLE IN WATER, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM.
BR9808888A (en) Dosage forms and method of improving male erectile dysfunction
DE59601880D1 (en) METHOD FOR PRODUCING HYDROPHILER OR PARTIAL HYDROPHILER, INORGANIC AEROGELE
CO5150154A1 (en) SUBSTRATE COMPOSITION AND METHOD FOR USE FOR THE SEQUESTRAY OF SKIN IRRITANTS
AR004483A1 (en) COMPOUNDS FOR THERAPY USE INCLUDING A 1,3-PROPANE DIOL WASTE AS A BINDING AGENT BETWEEN FATTY ACID WASTE AND A BIOACTIVE WASTE, USES OF THESE COMPOUNDS AND MEDICINES, FOODS AND TREATMENT AND TREATMENT TO SUCH COMPOUNDS
DE3769379D1 (en) INFLAMMATORY ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR CONTROLLING INFLAMMATION.
ES2130638T3 (en) SYSTEM FOR THE RELEASE OF ACTIVE SUBSTANCE, FILMOGEN, VAPORIZABLE, FOR USE IN PLANTS.
MX9605419A (en) Liquid detergent containing polyhydroxy fatty acid amide and toluene sulfonate salt.
SV2004001556A (en) ACID PREPARATIONS OF INSULIN WITH IMPROVED STABILITY
EE9700145A (en) Cycloalkanepyridines, their method of preparation, their use in the manufacture of medicinal products and medicinal products containing these compounds
ES2187201T3 (en) USE OF STEROLES AND STEROLESTERS TO NANOESCALA.
ES2113095T3 (en) SOLID PREPARATION FOR QUICK RELEASE, ITS PRODUCTION AND ITS USE.
ES2141208T3 (en) USE OF AN EFFECTIVE AMOUNT OF ACTIVE SUBSTANCES FOR THE TREATMENT OF MIXED SKIN.
DE4495520T1 (en) Process and pharmaceutical composition for the targeted application of active ingredients
BR9609499A (en) Ionene polymer tablet method for making a tablet ionene polymer composition and method for controlling the growth of microorganisms in an aqueous system
ES2132556T3 (en) NEW DERIVATIVE OF BENZO-TIADIAZINA, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.
TR199801104T2 (en) Lyophilized liposomes containing PGE-1 used in the treatment of erectile dysfunction.
ES2174533T3 (en) USE OF A MIXTURE OF A DIOL AND AN ALFA-HYDROXY ACID FOR THE TREATMENT OF HYPERQUERATOTIC SKIN DISEASES.
ES2070370T3 (en) 3,3'-DITIOBIS (PROPIONIC ACIDS) AND ITS ESTERS.
ITRM930286A0 (en) PHARMACEUTICAL COMPOSITION FOR RECTAL ADMINISTRATION IN THE TREATMENT OF HEADACHE AND RELATED METHOD OF PREPARATION AND USE.
MX9304185A (en) PRODUCT AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT FOR THE TREATMENT OF MASTITIS AND BOVINE MESTRITIS.